Item 7.01 Regulation FD Disclosure

A presentation of Oyster Point Pharma, Inc. (the "Company") dated July 1, 2021 regarding OC-01 (varenicline) nasal spray activity on SARS-CoV-2 infection is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The Company intends to use this presentation, in whole or in part, in future meetings with analysts, investors and others from time to time.

Channels for Disclosure of Information

Investors and others should note that the Company may announce material information to the public through filings with the Securities and Exchange Commission (the "SEC"), the Company's investor relations website (investors.oysterpointrx.com), press releases, public conference calls and public webcasts. The Company encourages investors and others to review the information disclosed through such channels as such information could be deemed to be material information. Please note that this list may be updated from time to time.

The information in this Item 7.01 of this Form 8-K and the attached Exhibits 99.1 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

The information contained in the presentation is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the SEC and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company does not undertake any duty or obligation to update or revise the information contained in this report, although the Company may do so from time to time as the management team believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the slide titled "Disclaimers and Forward Looking Statements" in the Exhibit 99.1 attached hereto.

Item 8.01 Other Events.

Preclinical Data Highlighting Potent Activity of OC-01 (Varenicline) and OC-02 (simpinicline) against SARS-CoV-2 Virus and Variants Press Release

On July 1, 2021, the Company issued a press release announcing preclinical data in non-human primates and in vitro models evaluating OC-01 (varenicline) nasal spray against SARS-CoV-2 and the alpha and beta variants, the viruses that cause COVID-19 disease, and preclinical data in in vitro models evaluating OC-02 (simpinicline) against SARS-CoV-2 alpha variant.

A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.       Description

99.1          July 1, 2021 Investor Slide Presentation

99.2          Press Release of Oyster Point Pharma, Inc. dated July 1, 2021

104         Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses